What Is Retatrutide?
Retatrutide is an investigational peptide studied for simultaneous agonism at three receptors — GLP-1, GIP, and glucagon. This overview summarizes what the preclinical literature describes, without making any treatment claims.
Updated August 8, 2026
The three receptor arms
GLP-1
The glucagon-like peptide-1 receptor is the best-characterized arm of the series. In model systems, agonism here is associated with insulin secretion in a glucose-dependent manner and with slowed gastric emptying.
GIP
Glucose-dependent insulinotropic polypeptide receptor activity is the arm tirzepatide added to the single-agonist template. Its contribution is an active research question rather than a settled one.
Glucagon
The third arm is what distinguishes retatrutide. Glucagon receptor activity is associated in the literature with energy expenditure and hepatic substrate handling, which is why retatrutide's metabolic profile is studied separately from the dual agonists.
How it compares to the rest of the series
Placing the compounds on a single axis of receptor coverage — semaglutide, then tirzepatide, then retatrutide — is the clearest way to reason about the series. Each step adds a receptor rather than replacing one, which is why comparative studies typically hold everything else constant and vary only the compound.
Laboratory handling
- Supplied lyophilized; keep sealed and cold until reconstitution
- Reconstitute with bacteriostatic water per your protocol
- Avoid vigorous shaking, which can shear peptide chains
- Label reconstituted vials with date and concentration
Research-use status
All compounds are sold strictly for laboratory research and development. They are not for human or veterinary use, and nothing on this page is medical advice.
Frequently asked questions
- Is retatrutide approved for human use?
- No. It is an investigational compound sold here strictly for laboratory research and development.
- What makes retatrutide a triple agonist?
- It is described in the literature as engaging the GLP-1, GIP, and glucagon receptors simultaneously, whereas semaglutide targets one and tirzepatide two.
- How is retatrutide reconstituted in a lab setting?
- Typically with bacteriostatic water added slowly down the vial wall, swirled rather than shaken, then labeled with date and concentration. See our reconstitution guide for the full procedure.
